Apogee Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders

On June 9, 2026, Apogee Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders. During the meeting, stockholders voted on three key proposals. First, Mark C. McKenna, Jennifer Fox, and William (BJ) Jones, Jr. were elected as Class III directors to serve until the 2029 Annual Meeting. Second, the appointment of Ernst & Young LLP as the company\'s independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified with an overwhelming majority. Finally, stockholders approved, on a non-binding advisory basis, the compensation of the company\'s named executive officers as disclosed in the proxy statement. As of the record date, April 15, 2026, there were 61,853,254 shares of common stock entitled to vote. The filing confirms the final voting results for each proposal, including votes for, withheld/against, abstentions, and broker non-votes. No significant changes to corporate strategy or clinical operations were announced in this filing.